The U.S. Department of Health and Human Services (HHS) is re-evaluating its stance on fluoride in drinking water by reconvening the Community Preventive Services Task Force, an independent panel of health experts. This move follows Health Secretary Robert F. Kennedy Jr.’s recent statement in Salt Lake City, indicating plans to halt the Centers for Disease Control and Prevention’s recommendation for community water fluoridation.
Fluoride, commonly added to public water supplies to prevent tooth decay, has been a controversial topic for decades. While the American Dental Association continues to support fluoridation as an effective dental health measure, concerns about potential health risks have gained traction.
The Environmental Protection Agency (EPA) will also review new scientific data on fluoride’s health effects. EPA Administrator Lee Zeldin confirmed that this effort is in collaboration with HHS, with the goal of re-evaluating the agency’s current enforceable fluoride limit of 4.0 milligrams per liter (mg/L). Currently, the U.S. Public Health Service recommends maintaining levels below 0.7 mg/L. Studies show that exposure above 1.5 mg/L can increase risks of bone fractures, thyroid dysfunction, and neurological damage.
In a landmark move, Utah became the first state to ban fluoride in public water systems after Governor Spencer Cox signed new legislation last month. The decision faced strong opposition from health experts and organizations, including the American Dental Association.
As of 2022, about 63% of Americans receive fluoridated water through their municipal systems. A 2024 federal court ruling ordered the EPA to tighten its standards, citing unacceptable health risks to children under current fluoride levels. While Kennedy claims links between fluoride and conditions like cancer, his statements remain unsubstantiated by definitive scientific evidence.


IMF Deputy Dan Katz Visits China as Key Economic Review Nears
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
UN Chief Says Gaza Operation “Fundamentally Wrong” as Concerns Over War Crimes Grow
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
U.S. Defense Chief Pete Hegseth Defends Controversial Second Strike on Suspected Drug-Smuggling Vessel
California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents
Trump and Lula Discuss Trade, Sanctions, and Security in “Productive” Phone Call
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 



